Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.47 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.47 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.47 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
| ▸ | ADK | P55263 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CASP6 | P55212 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.37 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.37 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.37 |
| ▸ | MC4R | P32245 | 2/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31627268 | 1.00 | CSNK1A1 (0.47) | CSNK1A1TYRO3DYRK1BNISCHMTOR | |
| SCHEMBL9287236 | 0.79 | NISCH (0.64) | CSNK1A1TYRO3DYRK1BNISCHMTOR | |
| SCHEMBL30222222 | 0.78 | NISCH (0.53) | CSNK1A1TYRO3DYRK1BNISCHMTOR | |
| SCHEMBL7537761 | 0.78 | CSNK1A1 (0.49) | CSNK1A1TYRO3DYRK1BNISCHMTOR | |
| SCHEMBL1369295 | 0.78 | NISCH (0.53) | CSNK1A1TYRO3DYRK1BNISCHMTOR | |
| SCHEMBL14886257 | 0.77 | NISCH (0.61) | CSNK1A1TYRO3DYRK1BNISCHMTOR | |
| SCHEMBL3600525 | 0.77 | NISCH (0.48) | CSNK1A1TYRO3DYRK1BNISCHMTOR | |
| SCHEMBL31627252 | 0.77 | CSNK1A1 (0.51) | CSNK1A1TYRO3DYRK1BNISCHMTOR | |
| SCHEMBL22408613 | 0.77 | CSNK1A1 (0.47) | CSNK1A1TYRO3DYRK1BNISCHMTOR | |
| Ammonia Solution, Strong SCHEMBL28778713 | 0.77 | NISCH (0.52) | CSNK1A1TYRO3DYRK1BNISCHMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025128834-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| EP-2868660-B1 | ANTITUMOR EFFECT POTENTIATOR COMPRISING AN IMIDAZOOXAZINE COMPOUND | TAIHO PHARMACEUTICAL CO LTD (JP) | 2017-12-27 | — | — | EP | disclosed |
| US-9375434-B2 | Antitumor effect potentiator composed of imidazooxazine compound | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2016-06-28 | — | — | US | disclosed |
| US-9289431-B2 | — | — | 2016-03-22 | — | — | US | disclosed |
| EP-2698372-B1 | NOVEL IMIDAZO-OXAZINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2016-02-03 | — | — | EP | disclosed |
| US-20150164909-A1 | ANTITUMOR EFFECT POTENTIATOR COMPOSED OF IMIDAZOOXAZINE COMPOUND | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2015-06-18 | — | — | US | disclosed |
| EP-2868660-A1 | ANTITUMOR EFFECT POTENTIATOR COMPOSED OF IMIDAZOOXAZINE COMPOUND | Taiho Pharmaceutical Co., Ltd. (JP) | 2015-05-06 | — | — | EP | disclosed |
| US-8772283-B2 | Imidazo-oxazine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-07-08 | — | — | US | disclosed |
| EP-2698372-A1 | NOVEL IMIDAZO-OXAZINE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2014-02-19 | — | — | EP | disclosed |
| US-20140005185-A1 | NOVEL IMIDAZO-OXAZINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-01-02 | — | — | US | disclosed |
| EP-1861079-A1 | ARYLSULFONYL BENZYL ETHERS AS 5-HT2A ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006097766-A1 | ARYLSULFONYL BENZYL ETHERS AS 5-HT2A ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150164909-A1 | ANTITUMOR EFFECT POTENTIATOR COMPOSED OF IMIDAZOOXAZINE COMPOUND | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, TPD52L2 | CSNK1A1 997/4885TYRO3 2085/4885DYRK1B 2330/4885 |
| US-20140005185-A1 | NOVEL IMIDAZO-OXAZINE COMPOUND OR SALT THEREOF | IKZF3, IKZF2, IKZF1 | CSNK1A1 180/4885TYRO3 2211/4885DYRK1B 1763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.